Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) — Dick de Zeeuw (2013) | RDL Network
Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)
Article 2013 en
Authors
DZ
Dick de Zeeuw
TA
Tadao Akizawa
RA
Rajiv Agarwal
Abstract
1 min read
BEACON will be the first event-driven trial to evaluate the effect of an oral antioxidant and anti-inflammatory drug in advanced CKD.
Hiddo J.L. Heerspink, Glenn M. Chertow, Tadao Akizawa, Paul Audhya, George L. Bakris, Angie Goldsberry, Melissa Krauth, Peter G. Linde, John J.V. McMurray, Colin J. Meyer, Hans‐Henrik Parving, Giuseppe Remuzzi, Heidi Christ‐Schmidt, Robert D. Toto, N. D. Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Dick de Zeeuw
Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L. Bakris, Melanie Chin, Heidi Christ‐Schmidt, Angie Goldsberry, Mark T. Houser, Melissa Krauth, Hiddo J.L. Heerspink, John J.V. McMurray, Colin J. Meyer, Hans‐Henrik Parving, Giuseppe Remuzzi, Robert D. Toto, Nosratola D. Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Glenn M. Chertow
David M. Charytan, Scott D. Solomon, Peter Ivanovich, Giuseppe Remuzzi, Mark E. Cooper, Janet B. McGill, Hans‐Henrik Parving, Patrick S. Parfrey, Ajay Singh, Emmanuel A. Burdmann, Andrew S. Levey, Kai‐Uwe Eckardt, John J.V. McMurray, Larry A. Weinrauch, Jiankang Liu, Brian Claggett, Eldrin F. Lewis, Marc A. Pfeffer
Chao Gao, R.T Wang, Kuniaki Takahashi, Hideyuki Kawashima, Robert‐Jan van Geuns, Yoshinobu Onuma, Marie‐Claude Morice, Piroze Davierwala, David R. Holmes, Michael J. Mack, F. W. Mohr, A. Pieter Kappetein, S. Taylor Head, Daniel J.F.M. Thuijs, Patrick W. Serruys
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.